selected scholarly activity
-
conferences
- 9. Abstract Title: Measurement of anti-factor Xa direct oral anticoagulant levels in the plasma samples from the perioperative anticoagulant use for surgery evaluation (PAUSE) study. Thrombosis Research. 7-8. 2018
- Lys 42, 43, 44 and Arg 12 of Thrombin Activable Fibrinolysis Inhibitor Comprise Thrombomodulin Binding Exosite Essential for Exerting Its Antifibrinolytic Activity. Arteriosclerosis, Thrombosis and Vascular Biology. 2017
- A novel substrate for use in a point of care thrombin generation assay. Journal of Thrombosis and Haemostasis. 211-211. 2015
- Lysine residues 42, 43, and 44 of thrombin activable fibrinolysis inhibitor contribute to its activation by the thrombin-thrombomodulin complex in a cooperative fashion. Journal of Thrombosis and Haemostasis. 264-264. 2015
- Rivaroxaban associates with factor Xa faster than apixaban: a potential explanation for their different effects on tests of coagulation. Journal of Thrombosis and Haemostasis. 556-556. 2015
- Clots formed from y '-fibrinogen are more resistant to lysis than those formed from? A-fibrinogen because of delayed plasminogen activation by tissue plasminogen activator. Journal of Thrombosis and Haemostasis. 304-304. 2013
- Different effects of antiplatelet vs. anticoagulant agents in mouse bleeding models. Journal of Thrombosis and Haemostasis. 890-890. 2013
- The effect of rivaroxaban and dabigatran on the surface architecture of clots formed from plasma enriched with different levels of autologous platelets. Journal of Thrombosis and Haemostasis. 468-469. 2013
- Zinc inhibits fibrinolysis by attenuating plasminogen activation and fibrin degradation. Journal of Thrombosis and Haemostasis. 793-793. 2013
- An in-Vitro Model Using Thromboelastography to Evaluate the Effects of Anticoagulants On Clot Formation in Plasma Enriched with Autologous Platelets. Blood. 1091-1091. 2012
- Kringle domains of plasmin are essential for efficient degradation of fibrin but not fibrinogen. Journal of Thrombosis and Haemostasis. E23-E23. 2012
- A randomized controlled trial comparing aspirin with dalteparin for the prevention of venous thromboembolism following total hip arthroplasty. Journal of Thrombosis and Haemostasis. 303-303. 2011
- Batroxobin and thrombin bind to distinct sites on fibrinogen and fibrin. Journal of Thrombosis and Haemostasis. 374-374. 2011
- High affinity binding of plasminogen to fibrin is not essential for efficient activation by tissue plasminogen activator. Journal of Thrombosis and Haemostasis. 847-847. 2011
- Histidine-rich glycoprotein binds fibrinogen with high affinity and modulates thrombin binding to the gamma '-chain. Journal of Thrombosis and Haemostasis. 759-759. 2011
- When assembled into their respective activation complexes, factors Xa, IXa, and VIIa are differentially protected from inhibition by the antithrombin/heparin complex. Journal of Thrombosis and Haemostasis. 277-278. 2011
- Zn2+ delays Glu-and Lys-plasminogen activation by tissue plasminogen activator and inhibits plasmin activity toward macromolecular substrates. Journal of Thrombosis and Haemostasis. 849-849. 2011
- The Role of Amino Acids 700-701 of the Factor Va Heavy Chain During Prothrombin Activation by Factor Xa.. Blood. 908-908. 2010
- Clots formed from gamma '-fibrinogen are resistant to lysis because of impaired plasminogen activation by t-PA. Journal of Thrombosis and Haemostasis. 6-6. 2010
- The role of activation peptide residues Lys42, Lys43, and Lys44 of TAFI in its activation by the thrombin-thrombomodulin complex. Journal of Thrombosis and Haemostasis. 32-32. 2010
- The Role of Lysine Residues 42, 43, and 44 in the Activation Peptide Region of TAFI in Its Activation by the Thrombin-Thrombomodulin Complex. Blood. 1235-1235. 2009
- Factor Va Cofactor Activity Is Dependent on the Interaction of Prothrombin with the Membrane Surface.. Blood. 2702-2702. 2007
- Understanding the Factor Va Cofactor Effect within Prothrombinase.. Blood. 2700-2700. 2007
- Controlling the Pathway for Prothrombin Activation by Prothrombinase.. Blood. 1695-1695. 2006
- Exposure of Anion Binding Exosite I of Thrombin Is Required and Sufficient for Timely Cleavage and Activation of Factor V and Factor VIII.. Blood. 1951-1951. 2005
- Cofactor Directed Catalysis.. Blood. 1715-1715. 2004
- Analysis of the inhibition of prothrombin activation by recombinant mutant substrates that produce only meizothrombin or fragment 1.2 : prethrombin-2.. Blood. 303A-303A. 2003
- Assessing pore formation by Bcl-2 during apoptosis in cell lines and human leukemic cells: Cysteine 158 in the alpha 5 helical loop is in an aqueous environment.. Blood. 174B-174B. 2000
-
journal articles
- 4D intravital imaging identifies platelets as the predominant cellular procoagulant surface in a mouse hemostasis model. Blood. 144:1116-1126. 2024
- A specific fluorescence resonance energy quenching–based biosensor for measuring thrombin activity in whole blood. Journal of Thrombosis and Haemostasis. 22:1627-1639. 2024
- Validation of the time to attain maximal clot amplitude after reaching maximal clot formation velocity parameter as a measure of fibrinolysis using rotational thromboelastometry and its application in the assessment of fibrinolytic resistance in septic patients: a prospective observational study: communication from the ISTH SSC Subcommittee on Fibrinolysis. Journal of Thrombosis and Haemostasis. 22:1223-1235. 2024
- Thrombin-activatable fibrinolysis inhibitor and sex modulate thrombus stability and pulmonary embolism burden in a murine model. Journal of Thrombosis and Haemostasis. 22:263-270. 2024
- Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. Journal of Thrombosis and Haemostasis. 21:1043-1054. 2023
- Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. PLoS ONE. 18:e0281673-e0281673. 2023
- Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. Vaccine Reports. 9:e12704-e12704. 2023
- SHock-INduced Endotheliopathy (SHINE): A mechanistic justification for viscoelastography-guided resuscitation of traumatic and non-traumatic shock. Frontiers in Physiology. 14:1094845. 2023
- Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality. Critical Care Explorations. 3:e0588-e0588. 2021
- Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID‐19: A single‐center prospective longitudinal study. Journal of Thrombosis and Haemostasis. 19:1546-1557. 2021
- Hypercoagulability and coronavirus disease 2019–associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. Journal of Trauma and Acute Care Surgery. 89:e177-e181. 2020
- Activated thrombin‐activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin‐dependent plasmin generation on thrombin‐activated platelets. Journal of Thrombosis and Haemostasis. 18:2364-2376. 2020
- The need for accurate D‐dimer reporting in COVID‐19: Communication from the ISTH SSC on fibrinolysis. Journal of Thrombosis and Haemostasis. 18:2408-2411. 2020
- Disruption of the kringle 1 domain of prothrombin leads to late onset mortality in zebrafish. Scientific Reports. 10:4049. 2020
- Defining trauma‐induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 18:740-747. 2020
- Purification of silica‐free DNA and characterization of its role in coagulation. Journal of Thrombosis and Haemostasis. 17:1860-1865. 2019
- An assay to measure levels of factor Xa inhibitors in blood and plasma. Journal of Thrombosis and Haemostasis. 17:1153-1159. 2019
- Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. Thrombosis and Haemostasis. 119:992-999. 2019
- Identification and characterization of a factor Va-binding site on human prothrombin fragment 2. Scientific Reports. 9:2436. 2019
- Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke. Journal of Thrombosis and Haemostasis. 16:1932-1940. 2018
- Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation. TH Open. 02:e190-e201. 2018
- Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. New England Journal of Medicine. 378:699-707. 2018
- Exosite 2-Directed Ligands Attenuate Protein C Activation by the Thrombin–Thrombomodulin Complex. Biochemistry. 56:3119-3128. 2017
- The impact of the endothelial protein C receptor on thrombin generation and clot lysis. Thrombosis Research. 152:30-37. 2017
- Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. Thrombosis and Haemostasis. 117:1509-1517. 2017
- Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity. Blood. 128:2834-2845. 2016
- Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells. Journal of Thrombosis and Haemostasis. 14:366-374. 2016
- Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis. Arteriosclerosis, Thrombosis and Vascular Biology. 35:2544-2553. 2015
- Evaluation of and recommendation for the nomenclature of the CPB2 gene product (also known as TAFI and proCPU): communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 13:2277-2278. 2015
- Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. Thrombosis and Haemostasis. 113:1278-1288. 2015
- Platelets: connecting clotting and lysis. Blood. 125:2459-2459. 2015
- Reduced Plasminogen Binding and Delayed Activation Render γ′-Fibrin More Resistant to Lysis than γA-Fibrin. Journal of Biological Chemistry. 289:27494-27503. 2014
- Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. Thrombosis and Haemostasis. 112:412-418. 2014
- Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty. ACP journal club. 158:800-800. 2013
- Batroxobin Binds Fibrin with Higher Affinity and Promotes Clot Expansion to a Greater Extent than Thrombin. Journal of Biological Chemistry. 288:16862-16871. 2013
- Insights into thrombin activatable fibrinolysis inhibitor function and regulation. Journal of Thrombosis and Haemostasis. 11:306-315. 2013
- Interactions of heparin and a covalently-linked antithrombin-heparin complex with components of the fibrinolytic system. Thrombosis and Haemostasis. 110:1180-1188. 2013
- Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis. Journal of Thrombosis and Thrombolysis. 33:412-415. 2012
- A High Affinity Interaction of Plasminogen with Fibrin Is Not Essential for Efficient Activation by Tissue-type Plasminogen Activator. Journal of Biological Chemistry. 287:4652-4661. 2012
- A revisit of the two-form kinetic model of prothrombinase: A rebuttal. Biophysical Chemistry. 160:75-76. 2012
- Histidine-rich Glycoprotein Binds Fibrin(ogen) with High Affinity and Competes with Thrombin for Binding to the γ′-Chain. Journal of Biological Chemistry. 286:30314-30323. 2011
- Biaxial ZnO−ZnS Nanoribbon Heterostructures. Journal of Physical Chemistry C. 113:4755-4757. 2009
- The Roles of Selected Arginine and Lysine Residues of TAFI (Pro-CPU) in Its Activation to TAFIa by the Thrombin-Thrombomodulin Complex. Journal of Biological Chemistry. 284:7059-7067. 2009
- Differences in prethrombin-1 activation with human or bovine factor Va can be attributed to the heavy chain. Thrombosis and Haemostasis. 102:623-633. 2009
- Activated thrombin‐activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation. Journal of Thrombosis and Haemostasis. 6:1600-1602. 2008
- The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase. Thrombosis and Haemostasis. 99:511-522. 2008
- Further Evidence for Two Functional Forms of Prothrombinase Each Specific for Either of the Two Prothrombin Activation Cleavages. Journal of Biological Chemistry. 282:32568-32581. 2007
- Condensation of silicon nanowires from silicon monoxide by thermal evaporation — An X-ray absorption spectroscopy investigation. Canadian Journal of Chemistry. 85:695-701. 2007
- The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease. Journal of Thrombosis and Haemostasis. 5:1250-1256. 2007
- A Control Switch for Prothrombinase. Journal of Biological Chemistry. 281:39194-39204. 2006
- The Structural Integrity of Anion Binding Exosite I of Thrombin Is Required and Sufficient for Timely Cleavage and Activation of Factor V and Factor VIII. Journal of Biological Chemistry. 281:18569-18580. 2006
- Isolation and characterization of cotiaractivase, a novel low molecular weight prothrombin activator from the venom of Bothrops cotiara. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics. 1764:863-871. 2006
- Incorporation of Factor Va into Prothrombinase Is Required for Coordinated Cleavage of Prothrombin by Factor Xa. Journal of Biological Chemistry. 280:27393-27401. 2005